Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America.
Clicks: 269
ID: 12884
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Star Article
77.0
/100
267 views
215 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the flexibility and ability to accurately dose patients with lupus. The Lupus Foundation of America undertook a survey to assess the current landscape of HCQ tolerability and adherence.
| Reference Key |
wallace2019hydroxychloroquinelupus
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Wallace, Daniel J;Tse, Karin;Hanrahan, Leslie;Davies, Rupert;Petri, Michelle A; |
| Journal | lupus science & medicine |
| Year | 2019 |
| DOI |
10.1136/lupus-2019-000317
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.